MedTrace Logo

Horizon Two: HR NDMM (MMRC-100)

NCT07053436 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-05-26

No results posted yet for this study

Summary

The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient-centric clinical research platform that enables longitudinal learning and sharing of knowledge and investigates multiple novel therapeutic strategies within one trial platform.

Conditions

  • High Risk Newly Diagnosed Multiple Myeloma

Interventions

DRUG

Bispecific Monoclonal Antibody and Triplet Therapy

Induction, Consolidation, and Maintenance Therapy Combining Linvoseltamab and Triplet Therapy

DRUG

Monoclonal Antibody with Stem Cell Transplant

Isatuximab-KRd with Autologous Stem Cell Transplant

Sponsors & Collaborators

  • Multiple Myeloma Research Consortium

    lead NETWORK

Principal Investigators

  • Hearn Jay Cho, MD, PhD · Multiple Myeloma Research Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2035-10-01
Completion
2035-10-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07053436 on ClinicalTrials.gov